patent number 381277 has been granted to the UNIVERSITY OF CANBERRA titled COMPOSITIONS FOR MODULATING CANCER STEM CELLS AND USES THEREFOR. The patent applicant responded to this objection by stating that the claimed compound does not pertain to mere forms/derivatives of known compounds. Therefore, the present invention does not fall under section 3(d) of the Patents Act. This patent falls under the category of Pharmaceuticals. Overall, this patent covers composition and methods for modulating cancer stem cells. More particularly, the present invention discloses the use of lysine demethylase (LSD) inhibitors and protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of LSD- and/or PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including non-metastatic and metastatic cancer and/or for preventing cancer recurrence.